What We Do

We discover and develop innovative drug products for treatment of cardio-metabolic diseases. Using our expertise in amino-lipid chemistry, we transform approved drugs or previously studied, biologically active agents to potentially make them better for patients.

 

Pipeline

» TP-252 for very high triglycerides

» TP-8252 for mixed dyslipidemia

» TP-452 for high LDL cholesterol

» TP-113 for type 2 diabetes

 
Learn more about our pipeline. »»

News

March 27, 2015
Thetis Advisor Andre Marette to Present At Boston Diabetes Summit on Novel Insulin Sensitizing Agent

March 4, 2015
Notice of Allowance on Composition of Matter Patent Expanding Type 2 Diabetes Portfolio

January 19, 2015
Thetis Initiates Diabetes Reversal Study On Metformin-DHA Agent

January 5, 2015
Pharma Industry Veteran Richard Daly Joins Thetis As Commercial Advisor